ema glp-1 vision loss recommendation november 2025 Last month, the European Medicines Agency recommended that product information for #semaglutide medicines— the active ingredient in #Ozempic, #Rybelsus, and #Wegovy — be updated to include non-arteritic anterior ischemic optic neuropathy or # Sudden Ozempic Blindness Reports Raise

Wondering about GLP-1 dosing approaches

A new meta-analysis of relevant clinical studies suggests that GLP 1 weight-loss drugs provide protection against heart attacks, strokes and premature death for up to 2.7 years

Health insurers are passing along cost for coverage in form of higher rates across the board, policy researcher says

Last week, Eli Lillys orforglipron has become the first oral, non-peptide GLP-1 receptor agonist to clear a Phase 3 trial, showing strong efficacy in reducing A1C (up to 1.6%) and body weight (up to 7.9%) in people with type 2 diabetes

PlexusDx provides compounded semaglutide from licensed pharmacies with transparent information about common and serious side effects